1. Глобальная стратегия лечения и профилактики бронхиальной астмы / пер. с англ., ред. А.С. Белевский. М.: Российское респираторное общество, 2015. 148 с.
2. Гришин О.В., Урюмцев Д.Ю., Гришин В.Г. Изменение легочного газообмена при резистивной нагрузке, не вызывающей чувство одышки // Физиол. человека. 2014. 40. (1). 101–105.
3. Bader N., Bosy-Westphal A., Dilba B. et al. Intra- and interindividual variability of resting energy expenditure in healthy male subjects – biological and methodological variability of resting energy expenditure // Br. J. Nutr. 2005. 94. (5). 843–849.
4. Boer L.M., Asijee G.M., van Schayck O.C. et al. How do dyspnoea scales compare with measurement of functional capacity in patients with COPD and at risk of COPD? // Prim. Care Respir. J. 2012. 21. (2). 202–207.
5. Carlone S., Balbi B., Bezzi M. et al. Health and social impacts of COPD and the problem of under-diagnosis // Multidiscip. Respir. Med. 2014. 9. (1). 63.
6. Davenport P.W., Chan P.Y., Zhang W. et al. Detection threshold for inspiratory resistive loads and respiratory-related evoked potentials // J. Appl. Physiol. 2007. 102. (1). 276–285.
7. Gottfried S.B., Altose M.D., Kelsen S.G. et al. The perception of changes in airflow resistance in normal subjects and patients with chronic airways obstruction // Chest. 1978. 73. (2, Suppl). 286–288.
8. Hochachka P.W. Intracellular convection, homeostasis and metabolic regulation // J. Exp. Biol. 2003. 206. (Pt. 12). 2001–2009.
9. Jones G.L., Killian K.J., Summers E. et al. Inspiratory muscle forces and endurance in maximum resistive loading // J. Appl. Physiol. 1985. 58. (5). 1608–1615.
10. Louhevaara V.A. Physiological effects associated with the use of respiratory protective devices // Scand. J. Work. Environ. Health. 1984. 10. (5). 275–281.
11. Mortola J.P. Implications of hypoxic hypometabolism during mammalian ontogenesis // Respir. Physiol. Neurobiol. 2004. 141. (3). 345–356.
12. Parshall M.B., Schwartzstein R.M., Adams L. et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea // Am. J. Respir. Crit. Care Med. 2012. 185. (4). 435–452.
13. Petty T.L. Definitions, causes, course, and prognosis of chronic obstructive pulmonary disease // Respir. Care Clin. N. Am. 1998. 4. (3). 345–358.
14. Rudolf M. The reality of drug use in COPD: the European perspective // Chest. 2000. 117. (2, Suppl). 29S–32S.
15. Shahab L., Jarvis M.J., Britton J. et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample // Thorax. 2006. 61. (12). 1043–1047.
16. Wiley R.L., Zechman F.W. Perception of added airflow resistance in humans // Respir. Physiol. 1966. 2. (1). 73–87.
17. Zechman F.W., Davenport P.W. Temporal differences in the detection of resistive and elastic loads to breathing // Respir. Physiol. 1978. 34. (2). 267–277.
Об авторах (для корреспонденции):
Гришин О.В. – д.м.н., главный научный сотрудник лаборатории функциональных резервов организма, e-mail: ovgrishin@physiol.ru
Урюмцев Д.Ю. – к.м.н., научный сотрудник лаборатории функциональных резервов организма, e-mail: piud@physiol.ru
Гультяева В.В. – к.б.н., старший научный сотрудник лаборатории функциональных резервов организма, e-mail: gultyaevavv@physiol.ru
Зинченко М.И. – к.м.н., научный сотрудник лаборатории функциональных резервов организма, e-mail: miz@physiol.ru
